HHS' OIG called on the CMS to collect medical-device specific information as part of its claims process, a move that could help the agency quickly identify poorly performing devices.
The industry is working to make sense of the data patients are collecting using wearables.
Federal regulators have approved the first continuous blood sugar monitor for diabetics that doesn't need backup finger prick tests.
The FDA's approval of a new type of duodenoscope could help cut down on hospital-acquired infections, which have been a problem for the G.I.-focused device.
Bayer will stop selling its sterilization device Essure outside the U.S., the company announced late Monday.
Scripps Health will hand off the day-to-day operations of San Diego's only cancer-targeting proton treatment center in early December. The center, like many others across the country, struggled to gain traction as the promise to advance cancer treatment came with a hefty price.
The FDA's recall of 465,000 Abbott Laboratories pacemakers earlier this week alerted medical-device makers that they increasingly need to be prepared to issue security updates and take cybersecurity issues more seriously.
A panel that advises HHS on outpatient hospital payments supports a decision by the CMS to drop payments for drug-coated balloons as of Dec. 31.
Biomedical leaders hope they'll be able to find bipartisan support to stall or repeal a 2.3% excise tax on all medical devices sold in the U.S. before it comes back online on Jan. 1, 2018.
More and more medical procedures are moving to the strip mall, thanks to high-deductible insurance plans that are turning patients into penny-pinchers. Hospital systems like Edward-Elmhurst Health are reacting, hedging their bets on what have been lucrative captive practices.
As policymakers and the drug and device industry look for new ways to bring treatments for life-threatening conditions to the market sooner, providers are concerned that expedited approvals could compromise patient care.
The $2 billion acquisition of NxStage will allow Fresenius to capture market share in the home dialysis segment and capitalize on payment models that favor coordinated care, analysts said.